Clinical trials: Hematopoietic Cell Transplantation
Cancer
Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to chronic graft-versus-host disease in patients who…
- Trial name
- NCT00957736
- Testing
- polymorphism analysis, laboratory biomarker analysis
- Where
- 3 sites in United States
- Volunteers
- 252 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Lymphoma, Myeloma
Allo Non-Myeloablative SCT Utilizing Mis-Matched Family Member Stem Cells Purged Using Campath
Allogeneic transplantation is used to treat many malignant and non-malignant diseases, though the potential toxicities of the procedure remain high.
- Conditions
- Lymphoma, Myeloma, Leukemia, Myelodysplasia
- Trial name
- NCT00580034
- Testing
- Campath Purged Non-myeloablative ASCT, Donor Apheresis
- Where
- United States
- Volunteers
- 176 people
- Sponsor
- David Rizzieri, MD
Graft-versus-host-disease, GVHD
CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease
The purpose of this study is to examine the safety and efficacy of the addition of BMS-986004 to standard of care Sirolimus (SIR)-based immune suppression.
- Conditions
- Graft-versus-host-disease, GVHD, GVHD, Acute
- Trial name
- NCT03605927
- Testing
- BMS-986004, Sirolimus, Tacrolimus
- Where
- 3 sites in United States
- Volunteers
- 45 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Lymphoma
Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00002461
- Testing
- filgrastim, sargramostim, carmustine
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Montefiore Medical Center
Allogeneic Hematopoietic Cell Transplantation
Precision Dosing of Alemtuzumab
The purpose of this study is to conduct a pilot trial of a Precision Dosing approach to alemtuzumab dosing for allogeneic hematopoietic cell transplantation of patients with non-malignant diseases.
- Trial name
- NCT03302754
- Testing
- Alemtuzumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Primary Immune Deficiency Disorder, Hematopoietic Stem Cell Transplantation
TCR Alpha/Beta Depletion for HSCT From Haploidentical and Unrelated Donors in the Treatment of PID
Treatment Study to assess of safety and efficiency of T cells receptor (TCR) alfa beta depleted graft for hematopoietic stem cell transplantation (HSCT) from haploidentical and unrelated donors in patients with primary…
- Trial name
- NCT02327351
- Testing
- Biological: TCR alfa beta T cell depletion
- Where
- Russia
- Volunteers
- 98 people
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Common Variable Immunodeficiency (CVID), Primary Immune Regulatory Disorder
Hematopoietic Stem Cell Transplantation (HSCT) for Common Variable Immunodeficiency (CVID) and Other Autoimmune Manifestations of Primary Immune Regulatory Disorders (PIRD)
This is a research protocol that will examine Hematopoietic Stem Cell Transplantation (HSCT) using a reduced conditioning regimen (RIC) with total body Irradiation (TBI) in those diagnosed with Common Variable Immunodeficiency…
- Conditions
- Common Variable Immunodeficiency (CVID), Primary Immune Regulatory Disorder, Immune Dysregulation, DiGeorge Syndrome
- Trial name
- CVID/PIRD (NCT07284641)
- Testing
- Hematopoietic stem cell transplant (HSCT)
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Paul Szabolcs
Thalassemia, Sickle Cell Disease
Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation
Allogeneic blood and marrow transplantation remains the only viable cure for children who suffer from many serious non-malignant hematological diseases. Transplantation, however, carries a high risk of fatal complications.
- Conditions
- Thalassemia, Sickle Cell Disease, Glanzmann Thrombasthenia, Wiskott-Aldrich Syndrome
- Trial name
- NCT01319851
- Testing
- Alefacept
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Emory University
Lymphoma
S0501 Fludarabine, Melphalan, and Donor Stem Cell Transplant Followed By Tacrolimus and Methotrexate in Treating Patients for Relapsed Lymphoma
RATIONALE: Giving low doses of chemotherapy, such as fludarabine and melphalan, before a donor bone marrow or peripheral blood stem cell transplant helps stop the growth of cancer cells.
- Trial name
- NCT00121186
- Testing
- fludarabine phosphate, melphalan, methotrexate
- Where
- 33 sites in United States
- Volunteers
- 1 people
- Sponsor
- SWOG Cancer Research Network
Hematologic Neoplasms
Prophylactic Early PN in HPT/BMT
Supplemental prophylactic early parenteral nutrition will be commenced 1 day prior to conditioning chemoradiotherapy in patients who are not already malnourished.
- Trial name
- NCT03083327
- Testing
- Parenteral nutrition., Pragmatic standard care.
- Where
- 3 sites in Australia, New Zealand
- Volunteers
- 408 people
- Sponsor
- University of Sydney
Myeloproliferative Disorders, Kidney Cancer
Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer
RATIONALE: Giving low doses of chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma
- Trial name
- NCT00787761
- Testing
- anti-thymocyte globulin, busulfan, cyclophosphamide
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Northside Hospital, Inc.
Hemoglobinopathy (Disorder), Severe Aplastic Anemia
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
This research is being done to learn if a new type of haploidentical transplantation using TCR alpha beta and CD19 depleted stem cell graft from the donor is safe and effective to treat the patient's underlying condition.
- Conditions
- Hemoglobinopathy (Disorder), Severe Aplastic Anemia, Bone Marrow Failure Syndrome
- Trial name
- NCT04356469
- Testing
- Haploidentical Hematopoietic Cell Transplantation
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Johns Hopkins All Children's Hospital
Graft vs Host Disease
Safety and Efficacy Study of T-Guard to Treat Steroid-resistant Acute GVHD
In this study, a combination of two antibodies both conjugated to a cell-killing toxin (so-called immunotoxins) will be evaluated.
- Trial name
- NCT02027805
- Testing
- T-Guard
- Where
- 2 sites in Germany, Netherlands
- Volunteers
- 20 people
- Sponsor
- Xenikos
Myeloma, Plasma-Cell, Lymphoma, Malignant
Multi-day Doses in Prevention of Nausea and Emesis
To assess emetic responses to multi-day doses of Palonosetron and Aprepitant and low dose dexamethasone +/- Prochlorperazine among patients with multiple myeloma and lymphoma undergoing autologous HSCT utilizing the Multinational…
- Trial name
- NCT00600353
- Testing
- Palonosetron, Aprepitant, Dexamethasone
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Kansas Medical Center
Hematologic Malignancies
Infection Rates of Myeloablative Allo SCT Recipients Receiving Neutropenic Diets Versus Non-Neutropenic Diets
In the transplant community, there is debate regarding the most appropriate food services for stem cell transplant patients. Recommendations regarding the use of low bacterial diets have been based on theoretical concepts of…
- Trial name
- NCT01687231
- Testing
- Non-neutropenic Diet
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Duke University
Viral Infection
TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
The purpose of this study is to use VSTs (virus-specific T cells) from a donor that is a partial HLA (human leukocyte antigen) match with the patient to treat viral infections after an allogeneic hematopoietic stem cell…
- Trial name
- TETRAVI (NCT04013802)
- Testing
- HLA-matched VSTs
- Where
- 2 sites in United States
- Volunteers
- 47 people
- Sponsor
- Baylor College of Medicine
Allogeneic Hematopoietic Stem Cell Transplantation, Myeloablative
Efficacy and Safety of rHuTPO on Platelet Engraftment After Allo-HSCT
Factors influencing platelet engraftment after allogeneic hematopoietic stem cell transplantation (Allo-HSCT) includes previous chemotherapy courses, conditioning regimen, HLA compatibility, source of stem cell, CD34+ cell count…
- Conditions
- Allogeneic Hematopoietic Stem Cell Transplantation, Myeloablative, Delayed Platelet Engraftment
- Trial name
- TPO (NCT01379391)
- Testing
- Recombinant Human Thrombopoietin (rHTPO)
- Where
- 9 sites in China
- Volunteers
- 80 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Hematopoietic Stem Cell Transplantation
Immunomonitoring After Hematopoietic Stem Cell Transplantation
Allogeneic hematopoietic stem cell transplantation (HSCT) remains the only curative option for many hematologic malignancies, in particular acute leukemias and myelodysplastic syndromes.
- Trial name
- Allo Monitor (NCT04635397)
- Where
- France
- Volunteers
- 61 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Kidney Failure, Chronic, Kidney Transplantation
Immunological Reset to Enable Access to Hla-compatible Kidney Transplantation in Highly Sensitized Patients (RESET)
The purpose of this clinical trial is to evaluate whether a temporary reprogramming of the immune system can help highly sensitized (hyperimmunized) patients with end-stage kidney disease safely receive a compatible kidney…
- Conditions
- Kidney Failure, Chronic, Kidney Transplantation, Alloimmunization, HLA Sensitization
- Trial name
- HIPER-RESET (NCT07607197)
- Testing
- Autologous Hematopoietic Stem Cell Transplantation
- Where
- Spain
- Volunteers
- 10 people
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Stem Cell Transplant, Adherence, Medication
BMT4me: Post-HSCT Medication Adherence mHealth App
This is a mixed methods, prospective longitudinal pilot RCT to evaluate the 1) acceptability of a newly developed mHealth app (BMT4me), 2) the feasibility of enrolling and retaining caregivers of children in the acute phase…
- Conditions
- Stem Cell Transplant, Adherence, Medication, Digital Health
- Trial name
- Bmt4me 2 (NCT05515497)
- Testing
- BMT4me 2.0 app
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Micah Skeens
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.